JPH09502187A - アンギオテンシン▲ii▼レセプターの拮抗薬 - Google Patents
アンギオテンシン▲ii▼レセプターの拮抗薬Info
- Publication number
- JPH09502187A JPH09502187A JP7508329A JP50832995A JPH09502187A JP H09502187 A JPH09502187 A JP H09502187A JP 7508329 A JP7508329 A JP 7508329A JP 50832995 A JP50832995 A JP 50832995A JP H09502187 A JPH09502187 A JP H09502187A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- angiotensin
- pharmaceutically acceptable
- acceptable salt
- receptor antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.慢性炎症性疾患の治療を必要とする哺乳動物にアンギオテンシンIIレセプ ター拮抗薬の有効量を投与することを特徴とする、該哺乳動物における慢性炎症 性疾患の治療方法。 2.アンギオテンシンIIレセプター拮抗薬が(E)−3−[2−n−ブチル−1 −{4−カルボキシフェニル)−メチル}−1H−イミダゾール−5−イル]−2− (2−チエニル)メチル−2−プロペン酸またはその医薬的に許容される塩である 請求項1記載の方法。 3.医薬的に許容される塩がメタンスルホン酸塩である請求項2記載の方法。 4.アンギオテンシンIIレセプター拮抗薬が(E)−3−[2−n−ブチル−1 −{4−カルボキシナフタ−1−イル)メチル}−1H−イミダゾール−5−イル] −2−(2−チエニル)メチル−2−プロペン酸またはその医薬的に許容される塩 である請求項1記載の方法。 5.アンギオテンシンIIレセプター拮抗薬が2−n−ブチル-4−クロロ−1 −[(2'−(1H−テトラゾール−5−イル)ビフェニル−4−イル)メチル]−5 −(ヒドロキシメチル)イミダゾールまたはその医薬的に許容される塩である請求 項1記載の方法。 6.アンギオテンシンIIレセプター拮抗薬が2−n−プロピル−4−ペンタフ ルオロエチル−1−[2'−(1H−テトラゾール−5−イル)ビフェニル−4−イ ル)メチル]イミダゾール−5−カルボン酸またはその医薬的に許容される塩であ る請求項1記載の方法。 7.アンギオテンシンIIレセプター拮抗薬が5,7−ジメチル−2−エチル− 3−(2'−(テトラゾール−5−イル)ビフェニル−4−イル)メチル−3H−イ ミダゾ[4,5−b]ピリジンまたはその医薬的に許容される塩である請求項1記 載の方法。 8.アンギオテンシンIIレセプター拮抗薬が2−エチル−4−{(2'−(1H− テトラゾール−5−イル)ビフェニル−4−イル)メトキシ]キノリンまたはその 医薬的に許容される塩である請求項1記載の方法。 9.アンギオテンシンIIレセプター拮抗薬が{[3−ブロモ−2−[2−テトラ ゾール−5−イル)フェニル]−5−ベンゾフラニル]メチル}−2−ブチル−4− クロロ−1H−イミダゾール−5−カルボン酸またはその医薬的に許容される塩 である請求項1記載の方法。 10.アンギオテンシンIIレセプター拮抗薬が2−n−ブチル−4−スピロシ クロペンチル−1−[(2'−(1H−テトラゾール−5−イル)ビフェニル−4− イル)メチル]−2−イミダゾリン−5−オンまたはその医薬的に許容される塩で ある請求項1記載の方法。 11.アンギオテンシンIIレセプター拮抗薬が(S)−N−(1−カルボキシ− 2−メチル−プロパ−1−イル)−N−ペンタノイル−N−[(2'−(1H−テト ラゾール−5−イル)ビフェニル−4−イル)メチル]アミンまたはその医薬的に 許容される塩である請求項1記載の方法。 12.アンギオテンシンIIレセプター拮抗薬が4'−[(2−n−ブチル−6− シクロヘキシルアミノカルボニル)アミノ−ベンゾイミダゾール−1−イル)メチ ル]ビフェニル−2−カルボン酸またはその医薬的に許容される塩である請求項 1記載の方法。 13.アンギオテンシンIIレセプター拮抗薬が1−(シクロヘキシルオキシカ ルボニルオキシ)エチル−2−エトキシ−1−[(2'−(1H−テトラゾール−5 −イル)ビフェニル−4−イル)メチル]−ベンゾイミダゾールまたはその医薬的 に許容される塩である請求項1記載の方法。 14.アンギオテンシンIIレセプター拮抗薬がAT1サブタイプレセプター拮 抗薬である請求項1記載の方法。 15.慢性炎症性疾患が関節炎、全身性自己免疫疾患または結合組織疾患から 選択される請求項1記載の方法。 16.関節炎が慢性関節リウマチ、リウマチ様脊椎炎、変形性関節炎、および 痛風性関節炎であるか、または、膝蓋骨軟骨軟化症である請求項15記載の方法 。 17.全身性自己免疫疾患が全身性紅斑性狼瘡、慢性関節リウマチ、糖尿病か ら選択され、結合組織疾患がシェーグレン病、多発性硬化症、スクロデルマから 選択されるか、または、混合結合組織疾患である請求項15記載の方法。 18.慢性炎症性疾患の治療薬の製造における、アンギオテンシンIIレセプタ ー拮抗薬またはその医薬的に許容される塩の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/115,968 US5824696A (en) | 1993-09-01 | 1993-09-01 | Medicaments |
US08/115,968 | 1993-09-01 | ||
PCT/US1994/010258 WO1995006410A1 (en) | 1993-09-01 | 1994-09-01 | Treatment of chronic inflammatory diseases by angiotension ii receptor antagonists |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006321842A Division JP2007084569A (ja) | 1993-09-01 | 2006-11-29 | アンギオテンシンiiレセプターの拮抗薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09502187A true JPH09502187A (ja) | 1997-03-04 |
JP3980632B2 JP3980632B2 (ja) | 2007-09-26 |
Family
ID=22364440
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50832995A Expired - Lifetime JP3980632B2 (ja) | 1993-09-01 | 1994-09-01 | アンギオテンシン▲ii▼レセプターの拮抗薬 |
JP2006321842A Pending JP2007084569A (ja) | 1993-09-01 | 2006-11-29 | アンギオテンシンiiレセプターの拮抗薬 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006321842A Pending JP2007084569A (ja) | 1993-09-01 | 2006-11-29 | アンギオテンシンiiレセプターの拮抗薬 |
Country Status (6)
Country | Link |
---|---|
US (1) | US5824696A (ja) |
EP (1) | EP0724387B1 (ja) |
JP (2) | JP3980632B2 (ja) |
AU (1) | AU7833594A (ja) |
DE (1) | DE69432595T2 (ja) |
WO (1) | WO1995006410A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000302695A (ja) * | 1999-02-19 | 2000-10-31 | Takeda Chem Ind Ltd | アンジオテンシンii受容体拮抗作用を有する化合物の経皮吸収剤 |
WO2005082905A1 (ja) * | 2004-02-26 | 2005-09-09 | Kyowa Hakko Kogyo Co., Ltd. | 二環性複素環化合物 |
JP2009242426A (ja) * | 1997-10-17 | 2009-10-22 | Ark Therapeutics Ltd | レニン−アンジオテンシン系の阻害剤の使用 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824696A (en) * | 1993-09-01 | 1998-10-20 | Smithkline Beecham Corporation | Medicaments |
CA2225465A1 (en) * | 1995-08-02 | 1997-02-13 | Newcastle University Ventures Limited | Benzimidazole compounds |
EP1105149A1 (en) * | 1998-08-13 | 2001-06-13 | University Of Southern California | Methods to increase blood flow to ischemic tissue |
AU2573800A (en) | 1999-02-19 | 2000-09-04 | Takeda Chemical Industries Ltd. | Percutaneous absorption preparations of compound having angiotensin ii receptor antagonism |
US6641811B1 (en) * | 2000-02-10 | 2003-11-04 | Cornell Research Foundation, Inc. | Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression |
PL356422A1 (en) | 2000-02-18 | 2004-06-28 | Takeda Chemical Industries, Ltd. | Tnf-alpha inhibitors |
EP1356815A4 (en) * | 2001-01-29 | 2007-03-07 | Takeda Pharmaceutical | ANALGESIC AND ANTI-INFLAMMATORY DRUGS |
WO2003035039A1 (en) * | 2001-10-25 | 2003-05-01 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
US6537590B1 (en) * | 2002-02-19 | 2003-03-25 | Troy J. Lee | Solution and the method of making the same for the treatment of osteoarthritis |
DE10335027A1 (de) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
WO2005044313A2 (en) * | 2003-11-06 | 2005-05-19 | Amersham Health As | Conjugates of angiotensin ii and an imaging moiety |
ATE493973T1 (de) | 2004-06-04 | 2011-01-15 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
EP2229177A1 (en) * | 2007-11-30 | 2010-09-22 | New York Medical College | Methods of isolating non-senescent cardiac stem cells and uses thereof |
US8512696B2 (en) | 2007-11-30 | 2013-08-20 | Autologous, Llc | Methods of isolating non-senescent cardiac stem cells and uses thereof |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185351A (en) * | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US5057522A (en) * | 1990-07-19 | 1991-10-15 | Merck & Co., Inc. | Anti-hypersensitive N2-tetrazole-β-glucuronide analog |
GB9201755D0 (en) * | 1992-01-28 | 1992-03-11 | British Bio Technology | Compounds |
US5212195A (en) * | 1992-05-13 | 1993-05-18 | Syntex (U.S.A.) Inc. | Substituted indole antagonists derivatives which are angiotensin II |
US5824696A (en) * | 1993-09-01 | 1998-10-20 | Smithkline Beecham Corporation | Medicaments |
-
1993
- 1993-09-01 US US08/115,968 patent/US5824696A/en not_active Expired - Lifetime
-
1994
- 1994-09-01 WO PCT/US1994/010258 patent/WO1995006410A1/en active IP Right Grant
- 1994-09-01 EP EP94929180A patent/EP0724387B1/en not_active Expired - Lifetime
- 1994-09-01 AU AU78335/94A patent/AU7833594A/en not_active Abandoned
- 1994-09-01 JP JP50832995A patent/JP3980632B2/ja not_active Expired - Lifetime
- 1994-09-01 DE DE69432595T patent/DE69432595T2/de not_active Expired - Lifetime
-
2006
- 2006-11-29 JP JP2006321842A patent/JP2007084569A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009242426A (ja) * | 1997-10-17 | 2009-10-22 | Ark Therapeutics Ltd | レニン−アンジオテンシン系の阻害剤の使用 |
JP2000302695A (ja) * | 1999-02-19 | 2000-10-31 | Takeda Chem Ind Ltd | アンジオテンシンii受容体拮抗作用を有する化合物の経皮吸収剤 |
WO2005082905A1 (ja) * | 2004-02-26 | 2005-09-09 | Kyowa Hakko Kogyo Co., Ltd. | 二環性複素環化合物 |
Also Published As
Publication number | Publication date |
---|---|
JP2007084569A (ja) | 2007-04-05 |
WO1995006410A1 (en) | 1995-03-09 |
EP0724387A4 (en) | 1997-06-18 |
DE69432595D1 (de) | 2003-06-05 |
EP0724387A1 (en) | 1996-08-07 |
AU7833594A (en) | 1995-03-22 |
JP3980632B2 (ja) | 2007-09-26 |
EP0724387B1 (en) | 2003-05-02 |
US5824696A (en) | 1998-10-20 |
DE69432595T2 (de) | 2004-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007084569A (ja) | アンギオテンシンiiレセプターの拮抗薬 | |
Walsh et al. | AT1 receptor characteristics of angiotensin analogue binding in human synovium. | |
EP0561939B1 (en) | Use of angiotensin ii receptor antagonists in the treatment of diabetic nephropathy | |
EP0561901A1 (en) | Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy | |
US5387601A (en) | Medicament | |
EP0561905A1 (en) | Use of angiotensin ii receptor antagonists in the treatment of macular degeneration | |
EP0561878A1 (en) | Use of angiotensin ii antagonist in the treatment of infarction | |
US20020058686A1 (en) | Medicament | |
EP0561977A1 (en) | Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke | |
EP0561876B1 (en) | Use of angiotensin ii receptor antagonists in the treatment of atheroma | |
EP0561896A1 (en) | Use of angiotensn ii receptor antagonists for the preparation of a medicament for improving cognitive function | |
US6028091A (en) | Medicament | |
WO1992010181A1 (en) | Use of angiotensin ii antagonists in the treatment of left ventricular hypertrophy | |
US6034114A (en) | Medicament | |
US6025380A (en) | Medicament | |
US20030050285A1 (en) | Medicament | |
US20020006949A1 (en) | Medicament | |
US20010016594A1 (en) | Medicament | |
JP3512793B6 (ja) | 糖尿病性腎症の治療におけるアンジオテンシン▲ii▼受容体拮抗剤の使用 | |
US20010051615A1 (en) | Medicament | |
US20030096851A1 (en) | Medicament | |
US20030069293A1 (en) | Medicament | |
US20030166700A1 (en) | Medicament |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050628 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050926 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051228 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061129 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20061228 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070612 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070628 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100706 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110706 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110706 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120706 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130706 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |